Basic Study
Copyright ©The Author(s) 2022.
World J Gastroenterol. Sep 14, 2022; 28(34): 4973-4992
Published online Sep 14, 2022. doi: 10.3748/wjg.v28.i34.4973
Table 1 List of all primers used to screen gastric cancer-associated long noncoding RNAs
Name
Forward-primer
Reverse-primer
GAPDHACCCACTCCTCCACCTTTGACTGTTGCTGTAGCCAAATTCGTT
H19TACAACCACTGCACTACCTGTGGAATGCTTGAAGGCTGCT
CCAT1CATTGGGAAAGGTGCCGAGAACGCTTAGCCATACAGAGCC
HOTAIRGGTAGAAAAAGCAACCACGAAGCACATAAACCTCTGTCTGTGAGTGCC
LINC00152CTCCAGCACCTCTACCTGTTGGGACAAGGGATTAAGACACACA
ZNFX1-AS1CCAGTTCCACAAGGTTACGCAGGTAGGCAGTTAGAA
PVT1CTTGAGAACTGTCCTTACGCAGATGAACCAGGTGAAC
GAS5CACAGGCATTAGACAGAAAGGAGCAGAACCATTAAG
SNHG12GACTTCCGGGGTAATGACAGGCCTTCTGCTTCCCATAGAG
TUG1TAGCAGTTCCCCAATCCTTGCACAAATTCCCATCATTCCC
CHET1CCCCACAAATGAAGACACTTTCCCAACACCCTATAAGAT
SUMP1P3ACTGGGAATGGAGGAAGATGAGAAAGGATTGAGGGAAAAG
GACAT3GGGGGCTTGTTTCTTTGTGTAGCATTCGGCTCTGACCTCTCAC
ABHD11-AS1GAACGGGATGAAGCCATTGGCTGATTCTGGACCTGCTG
GACAT2TGGATGCTTACAAAGGACTGGCTGCAATTACGGAAAGAGCTG
uc001lszGACGGCACCTACTACACCTTGCTGACCACCTTGTTGTTGAA
Table 2 The sequences of ZNFX1-AS1-shRNA1, ZNFX1-AS1-shRNA2 and NC-shRNA

Sequence
ZFAS1-shRNA1ACCGGTCGGGGGCCCAGGGTGGAGAGCACGAGGGCCTGGCCCAGGCACGGCCGGCGCCTCCGCCCTCGAGGAGGGCGTCACCTCAGCTCCCCCCGGCGGCGGAGCCGGCGGGCTCAGGCGGGCGCGGCTGAGGGGAGCGGACCGCGGGGGGCGGGAGATGACTGCGCCCAAGGCCTTTGCGGGCCTCAGCCGGCCCCAGAGGAAGGGGAACCCGTCGAGCGGTTTGGTGCGTGTGAAGCGCGACATGGCGAGGAAGCGGACAAGCCCGGGTGGCCCGGCGTGTAGAGGGAAGGGGGCGGGGCTAGACGCGGCCTGGACAACTACTAGAGCGCCTCGGGCTGTGCTGCTCGAGACTACATTTCCCAGAGCGACGCGCGCGGAGCGGGCGGGAAAGAGAGCGTTTCGGGTCCAGTGCGCAGGTGCGAAAGCCATCTTTGGTTATATAAGGGAGGTTCAGGAAGCCATTCGTTCTTTCGCGTCTGCGGTGCCCGGAGTGTGGTACTTCTCCTAGTTGCAGTCAGGCTTCATACGCTATTGTCCTGCCCGTTAGAGCAGCCAGCGGGTACAGAATGGATTTTGGAAGAGGGAGTCACCACTGGACCTCCAAGGAAGCCACGTGCAGACATCTACAACCTTCGATCTCCTGACGAGTTTATTGTTGGCCAAAACCAGGCTTTGATTGAACCAGGATGAATGCGGGTGTTGGAAGTAGAATATATATATACATATAAAATTGGTTGGGAGCCACGTGTACCAGTGTGTGTTGATCTTGGCTTGATTCAGTCTGCCTTGTAACAGAAACTGGCGATGGAATATGAGAGGAGCCCTCTGGAAAGAAAAGGACAGACCCTGTGCTTTCATGAAAGTGAAGATCTGGCTGAACCAGTTCCACAAGGTTACTGTATACATAGCCTGAGTTTAAAAGGCTGTGCCCACTTCAAGAATGTCATTGTTAGACTTTGAAATTTCTAACTGCCTACCTGCATAAAGAAAATAAAATCTTTTAAATCAAAAGCTAGC
ZFAS1-shRNA2TTACAAGGCAGACTGAATCTT
NC-shRNATTCTCCGAACGTGTCACGT
Table 3 List of primers used to detect mRNA expression of long noncoding RNA binding proteins
Name
Forward-primer (5’ to 3’)
Reverse-primer (5’to 3’)
GAPDHACCCACTCCTCCACCTTTGACTGTTGCTGTAGCCAAATTCGTT
UPF1GGTCCCTGATAATTATGGCGATGACGGCATAAACCTGGGAGTG
eIF4AIIIGGCATCTACGCTTACGGTTTCAGCCAACTCTCTTGTGGGA
IGF2BP1AGCTCCTTTATGCAGGCTCCGAGCCTTGAATTGGGCCTCT
FMRPCTCAAGGCTTGGCAGGGTATGCCGTGCCCCCTATTTCTGTA
LIN28AGATCAAAAGGAGACAGGTGCTAATAGCCCCCACCCATTGTG
IGF2BP2ACCCTCTCGGGTAAAGTGGAGTTGACAACGGCGGTTTCTG
FUSGCAAGATGGATTCCAGGGGTGTCCAGGAAAGTGAAAAGGGGG
ZC3H7BTGTGCAAAGGAGGAGATCGACACAGACGGAGAGTCCTTGGT
IGF2BP3CCTGGTGAAGACTGGCTACGCCAGCACCTCCCACTGTAAAT
CAPRIN1CTGCTGGCTGGCTAAGTCCGGCCGAGGGCATCGTG
Table 4 General characteristics and clinicopathological factors of gastric cancer patients and healthy control subjects
Variables
Gastric cancer (n = 15)
Healthy control (n = 15)
Gender
Male1212
Female33
Age (yr)
Mean6162
Range48-7047-80
Tumor site1
Upper third3-
Middle third4-
Lower third8-
Tumor size
≥ 5 cm6-
< 5 cm9-
Pathological differentiation2
Undifferentiated or poorly differentiated12-
Others3-
TNM classification3
I + II4-
III + IV11-
Lymphatic invasion3
Positive11-
Negative4-
Table 5 General characteristics and clinicopathological factors of gastric cancer patients and healthy control subjects
Variables
Healthy control (n = 60)
Gastritis/peptic ulcer (n = 60)
GIST (n = 60)
Gastric cancer (n = 60)
Gender
Male46373546
Female14232514
Age (yr)
Mean61606061
Range37-9137-8930-8537-91
Tumor site1
Upper third---13
Middle third---14
Lower third---33
Tumor size
≥ 5 cm---29
< 5 cm---31
Pathological differentiation2
Undifferentiated or poorly differentiated---45
Others---15
TNM classification3
I + II---20
III + IV---40
Lymphatic invasion3
Positive---43
Negative---17
Table 6 Correlation between the relative expression of long noncoding RNA HULC or ZNFX1-AS1 and clinicopathologic factors
Variables
Number of cases
P value
Gender
Male460.99
Female14
Age (yr)
≤ 61280.26
> 6132
Tumor site1
Upper third130.12
Middle third14
Lower third33
Tumor size
≥ 5 cm290.01
< 5 cm31
Pathological differentiation2
Undifferentiated or poorly differentiated450.55
Others15
TNM classification3
I + II200.02
III + IV40
Distant metastasis3
Positive50.97
Negative55
Lymphatic invasion3
Positive430.03
Negative17